This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
n10http://en.wikipedia.org/w/index.php?title=Donitriptan&action=
dcthttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
dbpedia-wikidatahttp://wikidata.dbpedia.org/resource/
n17http://commons.wikimedia.org/wiki/Special:FilePath/Donitriptan.svg?width=
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n18http://rdf.freebase.com/ns/m.
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://wikidata.org/entity/
n16http://en.wikipedia.org/w/index.php?title=Donitriptan&oldid=
owlhttp://www.w3.org/2002/07/owl#
n11http://commons.wikimedia.org/wiki/Special:FilePath/Donitriptan.
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
dbrhttp://dbpedia.org/resource/
Subject Item
dbr:Donitriptan
dbo:thumbnail
n17:300
owl:sameAs
n4:Q19597008 dbpedia-wikidata:Q19597008 n18:012j2qxq
foaf:isPrimaryTopicOf
wikipedia-en:Donitriptan
rdfs:comment
Donitriptan (INN) (code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed. It acts as a high-affinity, high-efficacy/near-full agonist of the 5-HT1B (pKi = 9.4–10.1; IA = 94%) and 5-HT1D receptors (pKi = 9.3–10.2; IA = 97%), and is among the most potent of the triptan series of drugs. Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.
rdfs:label
Donitriptan
dbo:abstract
Donitriptan (INN) (code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed. It acts as a high-affinity, high-efficacy/near-full agonist of the 5-HT1B (pKi = 9.4–10.1; IA = 94%) and 5-HT1D receptors (pKi = 9.3–10.2; IA = 97%), and is among the most potent of the triptan series of drugs. Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.
dbo:wikiPageEditLink
n10:edit
dbo:wikiPageExtracted
2019-08-12T21:48:43Z
dbo:wikiPageHistoryLink
n10:history
dbo:wikiPageID
44860314
dbo:wikiPageLength
4654
dbo:wikiPageModified
2019-08-12T21:48:39Z
dbo:wikiPageOutDegree
26
dbo:wikiPageRevisionID
910555809
dbo:wikiPageRevisionLink
n16:910555809
dbp:wikiPageUsesTemplate
dbt:Reflist dbt:Piperazines dbt:Nervous-system-drug-stub dbt:Serotonergics dbt:Antimigraine_preparations dbt:Drugbox
dct:subject
dbc:Aromatic_nitriles dbc:5-HT1D_agonists dbc:Abandoned_drugs dbc:Antimigraine_drugs dbc:Triptans dbc:Indole_ethers_at_the_benzene_ring dbc:Phenylpiperazines dbc:5-HT1B_agonists
foaf:depiction
n11:svg
Subject Item
wikipedia-en:Donitriptan
foaf:primaryTopic
dbr:Donitriptan
Subject Item
dbr:C23H25N5O2
dbo:wikiPageRedirects
dbr:Donitriptan